United Biomedical Inc (聯亞生技) yesterday announced that the interim analysis of phase 2 trials for its COVID-19 vaccine, UB-612, showed that the jab’s safety and immunogenicity met the drugmaker’s expectations.
United Biomedical would submit a final report to the Food and Drug Administration (FDA) by the end of this month and apply for emergency use authorization, UBI Pharma Inc (聯亞藥業) spokesperson Vivien Fan (范瀛云) told an online news conference on behalf of the firm’s parent company.
The announcement came after Medigen Vaccine Biologics Corp (高端疫苗) on June 10 said it was seeking FDA’s emergency use authorization for its COVID-19 vaccine after reporting positive phase 2 trial results.
United Biomedical is planning to complete phase 2 trial data unblinding in late November and is considering conducting phase 3 trials in India, aiming to recruit 11,000 participants, Fan said.
UB-612 is a multitope protein/peptide-based vaccine. United Biomedical on Feb. 26 started enrolling participants for the phase 2 trials and completed the enrollment phase on May 18.
The drug was administered to 3,850 participants in the multi-regional, randomized, double-blinded and placebo-controlled study, the company said.
They were divided into three age groups: twelve to 18 years, 19 to 64 years, and 65 and older, it said, adding that one in every seven participants was administered a placebo.
Fan said that phase 2 trial results indicated that UB-612 was safe, as no adverse reactions were recorded throughout trials.
The vaccine showed no significant side effects, as 1.93 percent of participants who received UB-612 had a fever, compared with 1.81 percent in the placebo group, she said.
Among those who received the vaccine, 37.47 percent reported feeling tired, compared with 38.34 percent in the placebo group, Fan said.
Among those who received UB-612, 17.01 percent reported having a headache, 35.69 percent reported sore muscles and 10.23 percent said they had diarrhea, compared with 18.63 percent, 17.72 percent and 9.95 percent respectively for those who were given a placebo, she added.
Immunogenicity results were promising, as 95.65 percent of trial participants in the 19-to-64 age bracket showed a COVID-19 specific immune memory 28 days after receiving the second dose of the vaccine, she said, adding that the figure was 88.57 percent for older participants.
The geometric mean titer (GMT), which indicates the level of neutralizing antibody response, was 102.3, United Biomedical said, adding that the result met its expectations based on phase 1 trials.
The GMT figure also showed lot-to-lot consistency, meeting the FDA’s standards for emergency use authorization, it said.
The phase 2 trials also indicated a similar degree of GMT figure when tested for the Delta variant of COVID-19, the company added.
SETBACK: Apple’s India iPhone push has been disrupted after Foxconn recalled hundreds of Chinese engineers, amid Beijing’s attempts to curb tech transfers Apple Inc assembly partner Hon Hai Precision Industry Co (鴻海精密), also known internationally as Foxconn Technology Group (富士康科技集團), has recalled about 300 Chinese engineers from a factory in India, the latest setback for the iPhone maker’s push to rapidly expand in the country. The extraction of Chinese workers from the factory of Yuzhan Technology (India) Private Ltd, a Hon Hai component unit, in southern Tamil Nadu state, is the second such move in a few months. The company has started flying in Taiwanese engineers to replace staff leaving, people familiar with the matter said, asking not to be named, as the
The prices of gasoline and diesel at domestic fuel stations are to rise NT$0.1 and NT$0.4 per liter this week respectively, after international crude oil prices rose last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) announced yesterday. Effective today, gasoline prices at CPC and Formosa stations are to rise to NT$27.3, NT$28.8 and NT$30.8 per liter for 92, 95 and 98-octane unleaded gasoline respectively, the companies said in separate statements. The price of premium diesel is to rise to NT$26.2 per liter at CPC stations and NT$26 at Formosa pumps, they said. The announcements came after international crude oil prices
DOLLAR SIGNS: The central bank rejected claims that the NT dollar had appreciated 10 percentage points more than the yen or the won against the greenback The New Taiwan dollar yesterday fell for a sixth day to its weakest level in three months, driven by equity-related outflows and reactions to an economics official’s exchange rate remarks. The NT dollar slid NT$0.197, or 0.65 percent, to close at NT$30.505 per US dollar, central bank data showed. The local currency has depreciated 1.97 percent so far this month, ranking as the weakest performer among Asian currencies. Dealers attributed the retreat to foreign investors wiring capital gains and dividends abroad after taking profit in local shares. They also pointed to reports that Washington might consider taking equity stakes in chipmakers, including Taiwan Semiconductor
A German company is putting used electric vehicle batteries to new use by stacking them into fridge-size units that homes and businesses can use to store their excess solar and wind energy. This week, the company Voltfang — which means “catching volts” — opened its first industrial site in Aachen, Germany, near the Belgian and Dutch borders. With about 100 staff, Voltfang says it is the biggest facility of its kind in Europe in the budding sector of refurbishing lithium-ion batteries. Its CEO David Oudsandji hopes it would help Europe’s biggest economy ween itself off fossil fuels and increasingly rely on climate-friendly renewables. While
RSS